Use of Noninvasive Imaging in Cardiac Amyloidosis

被引：5
作者：
Quintana-Quezada R.A. [1 ]
Yusuf S.W. [1 ]
Banchs J. [1 ]
机构：
[1] Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1451, Houston, 77030, TX
来源：
Current Treatment Options in Cardiovascular Medicine | 2016年 / 18卷 / 7期
关键词：
Cardiac amyloidosis; Cardiac magnetic resonance; Cardio-oncology; Endomyocardial biopsy;
D O I：
10.1007/s11936-016-0469-3
中图分类号：
学科分类号：
摘要：
Cardiac involvement in amyloidosis is associated with poor outcomes. The standard test for the diagnosis of cardiac amyloidosis is endomyocardial biopsy but given current advances in noninvasive imaging, the diagnosis is frequently obtained or strongly suspected without biopsy. Echocardiography is the most utilized cardiac imaging modality, particularly myocardial strain measures with this modality have been found to be a predictor of clinical outcomes, superior to traditional parameters. Other known imaging modalities with new, useful protocols for this pathology include nuclear imaging and cardiac magnetic resonance (CMR). In particular, CMR has excellent sensitivity and specificity. © 2016, Springer Science+Business Media New York.
引用
收藏
相关论文
共 61 条
  • [1] Merlini G., Bellotti V., Molecular mechanisms of amyloidosis, N Engl J Med, 349, 6, pp. 583-596, (2003)
  • [2] Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Et al., Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis, Nat Med, 6, 6, pp. 643-651, (2000)
  • [3] Sousa M.M., Du Y.S., Fernandes R., Guimaraes A., Stern D., Saraiva M.J., Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways, J Neurosci, 21, pp. 7576-7586, (2001)
  • [4] Rogers J., Webster S., Lue L.F., Brachova L., Civin W.H., Emmerling M., Et al., Inflammation and Alzheimer’s disease pathogenesis, Neurobiol Aging, 17, pp. 681-686, (1996)
  • [5] Andersson K., Olofsson A., Nielsen E.H., Svehag S.E., Lundgren E., Only amyloidogenic intermediates of transthyretin induce apoptosis, Biochem Biophys Res Commun, 294, pp. 309-314, (2002)
  • [6] Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Et al., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo, Nature, 416, pp. 535-539, (2002)
  • [7] Sipe J.D., Benson M.D., Buxbaum J.N., Ikeda S., Merlini G., Saraiva M.J., Et al., Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis, Amyloid, 21, pp. 221-224, (2014)
  • [8] Kyle R.A., Linos A., Beard C.M., Linke R.P., Gertz M.A., O'Fallon W.M., Et al., Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989, Blood, 79, 7, pp. 1817-1822, (1992)
  • [9] Pinney J.H., Smith C.J., Taube J.B., Lachmann H.J., Venner C.P., Gibbs S.D., Et al., Systemic amyloidosis in England: an epidemiological study, Br J Haematol, 161, pp. 525-532, (2013)
  • [10] Dubrey S.W., Cha K., Anderson J., Chamarthi B., Reisinger J., Skinner M., Et al., The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement, QJM, 91, 2, pp. 141-157, (1998)
1234567